Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer.

Siddharth Mehra Vanessa T Garrido Austin R Dosch Purushottam Lamichhane Supriya Srinivasan Samara P Singh Zhiqun Zhou Iago De Castro Silva Chandrashekar Joshi Yuguang J Ban Jashodeep Datta Eli Gilboa Nipun B Merchant Nagaraj S Nagathihalli

Published in: Cancer research communications (2023)

Immunotherapeutic agents are ineffective against pancreatic cancer, mainly due to the immunosuppressive tumor microenvironment and stromal desmoplasia. Our current study demonstrates the therapeutic utility of a novel gut microbial metabolite, Uro A, to remodel the stromal-immune microenvironment and improve overall survival with anti-PD-1 therapy in pancreatic cancer.

Keyphrases

bone marrow
stem cells
free survival
mesenchymal stem cells
cell therapy